Share This Author
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
- H. Hurwitz, L. Fehrenbacher, F. Kabbinavar
- MedicineThe New England journal of medicine
- 3 June 2004
TLDR
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
- A. Rittmeyer, F. Barlesi, D. Gandara
- MedicineThe Lancet
- 21 January 2017
Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer.
- David H. Johnson, L. Fehrenbacher, F. Kabbinavar
- Medicine, BiologyJournal of clinical oncology : official journal…
- 1 June 2004
TLDR
First‐Line Atezolizumab plus Chemotherapy in Extensive‐Stage Small‐Cell Lung Cancer
- L. Horn, A. Mansfield, Stephen V. Liu
- MedicineThe New England journal of medicine
- 25 September 2018
TLDR
Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer.
- F. Kabbinavar, H. Hurwitz, E. Bergsland
- Medicine, BiologyJournal of clinical oncology : official journal…
- 2003
TLDR
Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial.
- F. Kabbinavar, J. Schulz, W. Novotny
- MedicineJournal of clinical oncology : official journal…
- 1 June 2005
TLDR
Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab.
- F. Scappaticci, J. Skillings, H. Hurwitz
- MedicineJournal of the National Cancer Institute
- 15 August 2007
TLDR
Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer.
- H. Hurwitz, L. Fehrenbacher, F. Kabbinavar
- MedicineJournal of clinical oncology : official journal…
- 20 May 2005
TLDR
Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial.
- R. Herbst, Yan Sun, B. Johnson
- Medicine, BiologyThe Lancet. Oncology
- 1 July 2010
Natural history of rising serum prostate-specific antigen in men with castrate nonmetastatic prostate cancer.
- Matthew R. Smith, F. Kabbinavar, C. Higano
- Medicine, BiologyJournal of clinical oncology : official journal…
- 1 May 2005
TLDR
...
...